A股異動丨海利生物漲停 被認定為農業產業化上海市重點龍頭企業
格隆匯12月10日丨海利生物(603718.SH)漲停,報13.2元,總市值85億元。

海利生物12月6日晚公告,公司被認定為農業產業化上海市重點龍頭企業,有效期至2021年10月30日止。公司可享受上海市關於支持重點龍頭企業發展的一系列扶持政策,對未來發展將產生積極影響。海利生物是集研發、生產、銷售、服務於一體的專業化獸用生物製品企業,產品主要為畜用、禽用動物疫苗,有15種豬用疫苗和16種禽用疫苗產品,其中豬圓環滅活疫苗與豬藍耳活疫苗是主打產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.